Published in Cancer Res on May 15, 2004
The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J (2008) 1.73
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Ceramide-rich platforms in transmembrane signaling. FEBS Lett (2010) 1.46
Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol (2008) 1.35
Lipid raft: A floating island of death or survival. Toxicol Appl Pharmacol (2012) 1.25
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One (2010) 1.13
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol (2012) 1.06
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One (2009) 1.05
Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta (2013) 1.04
Formation and function of ceramide-enriched membrane platforms with CD38 during M1-receptor stimulation in bovine coronary arterial myocytes. Am J Physiol Heart Circ Physiol (2008) 0.98
Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J Biol Chem (2010) 0.97
Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol (2008) 0.96
ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res (2013) 0.95
HIF-1α depletion results in SP1-mediated cell cycle disruption and alters the cellular response to chemotherapeutic drugs. Cell Cycle (2011) 0.93
Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J (2006) 0.92
Ceramide signaling in mammalian epidermis. Biochim Biophys Acta (2013) 0.92
Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Front Physiol (2014) 0.91
Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Dis (2010) 0.86
Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc Natl Acad Sci U S A (2008) 0.85
Recent advances in the immunobiology of ceramide. Exp Mol Pathol (2006) 0.83
Differential activation of acid sphingomyelinase and ceramide release determines invasiveness of Neisseria meningitidis into brain endothelial cells. PLoS Pathog (2014) 0.83
Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Met Based Drugs (2008) 0.83
Re-configuration of sphingolipid metabolism by oncogenic transformation. Biomolecules (2014) 0.83
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis (2012) 0.82
Multifaceted nature of membrane microdomains in colorectal cancer. World J Gastroenterol (2011) 0.82
Accumulated bending energy elicits neutral sphingomyelinase activity in human red blood cells. Biophys J (2012) 0.79
Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cells. Cell Death Discov (2016) 0.79
Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis. J Surg Res (2010) 0.79
Lysosomal ceramide generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis. Cell Death Dis (2015) 0.78
The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respir Med J (2010) 0.78
Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin. Oncotarget (2016) 0.78
Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. PLoS One (2013) 0.78
Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells. BMC Cancer (2011) 0.78
Sphingolipid Organization in the Plasma Membrane and the Mechanisms That Influence It. Front Cell Dev Biol (2017) 0.78
Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. Laryngoscope (2016) 0.77
Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells. Evid Based Complement Alternat Med (2014) 0.77
Importance of the difference in surface pressures of the cell membrane in doxorubicin resistant cells that do not express Pgp and ABCG2. Cell Biochem Biophys (2013) 0.77
Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells. BMC Complement Altern Med (2013) 0.77
Membrane Transition Temperature Determines Cisplatin Response. PLoS One (2015) 0.77
Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment. Mediators Inflamm (2015) 0.77
Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells. J Clin Invest (2015) 0.77
Targeting Phospholipid Metabolism in Cancer. Front Oncol (2016) 0.77
Mechanisms by Which Pleiotropic Amphiphilic n-3 PUFA Reduce Colon Cancer Risk. Curr Colorectal Cancer Rep (2014) 0.76
Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease. Cell Mol Immunol (2011) 0.76
Sphingolipids are involved in N-methyl-N'-nitro-N-nitrosoguanidine-induced epidermal growth factor receptor clustering. Biochem Biophys Res Commun (2005) 0.75
Mechanical compression insults induce nanoscale changes of membrane-skeleton arrangement which could cause apoptosis and necrosis in dorsal root ganglion neurons. Biosci Biotechnol Biochem (2014) 0.75
Preparation of a functional fluorescent human Fas ligand extracellular domain derivative using a three-dimensional structure guided site-specific fluorochrome conjugation. Springerplus (2016) 0.75
Emerging role of chemoprotective agents in the dynamic shaping of plasma membrane organization. Biochim Biophys Acta (2017) 0.75
Ceramide-1-phosphate protection of cochlear hair cells against cisplatin ototoxicity. Toxicol Rep (2016) 0.75
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J (2013) 2.70
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood (2005) 2.01
HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol (2003) 1.96
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood (2002) 1.84
Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood (2012) 1.77
Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 1.68
Clonal architecture of chronic myelomonocytic leukemias. Blood (2013) 1.67
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene (2005) 1.64
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol (2009) 1.64
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature (2006) 1.59
High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol (2007) 1.56
What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood (2009) 1.52
Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene (2003) 1.52
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler Thromb Vasc Biol (2005) 1.49
Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood (2006) 1.48
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47
Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration*. Crit Care Med (2014) 1.47
Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun (2003) 1.42
Vital functions for lethal caspases. Oncogene (2005) 1.40
SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma (2012) 1.39
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res (2004) 1.38
Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med (2005) 1.38
Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int (2008) 1.38
Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem (2003) 1.36
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood (2011) 1.36
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2013) 1.35
Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol (2003) 1.32
Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res (2011) 1.32
Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol (2006) 1.28
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood (2013) 1.25
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood (2009) 1.24
Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res (2006) 1.24
HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J (2006) 1.21
Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signal (2005) 1.20
Human defensins as cancer biomarkers and antitumour molecules. J Proteomics (2009) 1.20
Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol (2010) 1.20
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther (2007) 1.17
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 1.16
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood (2013) 1.16
The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene (2003) 1.15
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood (2004) 1.14
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver Int (2011) 1.14
Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest (2014) 1.13
UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem (2005) 1.13
Aryl hydrocarbon receptor- and calcium-dependent induction of the chemokine CCL1 by the environmental contaminant benzo[a]pyrene. J Biol Chem (2006) 1.13
Rituximab inhibits B-cell receptor signaling. Blood (2009) 1.13
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene (2003) 1.12
The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol (2008) 1.11
Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid (2008) 1.10
Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol (2008) 1.10
Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol (2008) 1.09
Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis (2006) 1.09
Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica (2011) 1.08
Cadmium induces caspase-independent apoptosis in liver Hep3B cells: role for calcium in signaling oxidative stress-related impairment of mitochondria and relocation of endonuclease G and apoptosis-inducing factor. Free Radic Biol Med (2004) 1.08
Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res (2007) 1.07
TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions. Cancer Res (2007) 1.07